These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
281 related articles for article (PubMed ID: 8869093)
1. Neoadjuvant chemotherapy (MVAC) in locally invasive bladder cancer. Sagaster P; Flamm J; Flamm M; Mayer A; Donner G; Oberleitner S; Havelec L; Lepsinger L; Ludwig H Eur J Cancer; 1996 Jul; 32A(8):1320-4. PubMed ID: 8869093 [TBL] [Abstract][Full Text] [Related]
2. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer. McConkey DJ; Choi W; Shen Y; Lee IL; Porten S; Matin SF; Kamat AM; Corn P; Millikan RE; Dinney C; Czerniak B; Siefker-Radtke AO Eur Urol; 2016 May; 69(5):855-62. PubMed ID: 26343003 [TBL] [Abstract][Full Text] [Related]
3. Relative efficacy of perioperative gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management of locally advanced urothelial carcinoma of the bladder. Yeshchina O; Badalato GM; Wosnitzer MS; Hruby G; RoyChoudhury A; Benson MC; Petrylak DP; McKiernan JM Urology; 2012 Feb; 79(2):384-90. PubMed ID: 22196406 [TBL] [Abstract][Full Text] [Related]
4. Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses. Pfister C; Gravis G; Fléchon A; Soulié M; Guy L; Laguerre B; Mottet N; Joly F; Allory Y; Harter V; Culine S; Eur Urol; 2021 Feb; 79(2):214-221. PubMed ID: 32868138 [TBL] [Abstract][Full Text] [Related]
5. Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group Study JCOG0209. Kitamura H; Tsukamoto T; Shibata T; Masumori N; Fujimoto H; Hirao Y; Fujimoto K; Kitamura Y; Tomita Y; Tobisu K; Niwakawa M; Naito S; Eto M; Kakehi Y; Ann Oncol; 2014 Jun; 25(6):1192-8. PubMed ID: 24669010 [TBL] [Abstract][Full Text] [Related]
6. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Dash A; Pettus JA; Herr HW; Bochner BH; Dalbagni G; Donat SM; Russo P; Boyle MG; Milowsky MI; Bajorin DF Cancer; 2008 Nov; 113(9):2471-7. PubMed ID: 18823036 [TBL] [Abstract][Full Text] [Related]
7. The efficacy of neoadjuvant chemotherapy in invasive bladder cancer. Cam K; Yildirim A; Ozveri H; Turkeri L; Akdas A Int Urol Nephrol; 2002; 33(1):49-52. PubMed ID: 12090338 [TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy. Zargar H; Shah JB; van Rhijn BW; Daneshmand S; Bivalacqua TJ; Spiess PE; Black PC; Kassouf W; J Urol; 2018 Jun; 199(6):1452-1458. PubMed ID: 29329894 [TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant CMV chemotherapy plus radical cystectomy in locally advanced bladder cancer: the impact of pathologic response on long-term results. Scattoni V; Bolognesi A; Cozzarini C; Francesca F; Grasso M; Galli L; Torelli T; Campo B; Villa E; Rigatti P Tumori; 1996; 82(5):463-9. PubMed ID: 9063525 [TBL] [Abstract][Full Text] [Related]